Trial · NCT07907172
Expanded Donor Stem Cells for Poor Graft Function After Stem Cell Transplantation in Children
NCT07907172, Phase 1, Not yet recruiting, wang xiaodong
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Expanded Donor Stem Cells for Poor Graft Function After Stem Cell Transplantation in Children. Trials, record NCT07907172. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07907172
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Expanded Donor Stem Cells for Poor Graft Function After Stem Cell Transplantation in Children
- NCT number
- NCT07907172
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 3 participants, estimated
- Lead sponsor
- wang xiaodong
- Conditions
- Poor Graft Function, Hematopoietic Stem Cell Transplantation Complications
- Interventions
- Ex vivo HEB-001-expanded donor-derived CD34+ hematopoietic stem cells
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Participants With Treatment-Related Acute Adverse Events | From infusion (Day 0) through Day 30 | Number and percentage of participants experiencing infusion-related treatment-associated adverse events within 30 days, including fever (≥38.5°C), allergic reactions, or microbiologically confirmed infections. Adverse event types, severity (CTCAE v5.0), and the number with Grade ≥3 events will be described for each participant. |
| Primary | Participants With Evidence of Clonal Hematopoiesis or Driver Mutations | Before infusion (baseline), Day 100, and 1 year after infusion | Whole-exome sequencing will be used to describe detected hematopoietic driver mutations (including DNMT3A, TP53, and ASXL1) and variant allele frequencies; V(D)J sequencing will assess clonality. The number of participants with evidence of clonal hematopoiesis or relevant driver mutations will be reported at follow-up relative to baseline. |
| Secondary | Time to Neutrophil Recovery | From infusion (Day 0) through Day 100 | Elapsed days from cell infusion to the first of three consecutive days with an absolute neutrophil count (ANC) ≥0.5 × 10\^9/L. Individual recovery times and the median/range will be reported. |
| Secondary | Time to Platelet Recovery | From infusion (Day 0) through Day 100 | Elapsed days from cell infusion to the first day of a sustained platelet count ≥20 × 10\^9/L without platelet transfusion for at least 7 days. Individual recovery times and the median/range will be reported. |
| Secondary | Donor Chimerism Following Expanded Stem Cell Infusion | Days 30 and 100 after infusion | Donor-derived hematopoietic chimerism measured by short tandem repeat polymerase chain reaction (STR-PCR), expressed as percentage donor-derived cells; achievement of ≥90% donor chimerism will also be described. |
| Secondary | Overall Survival | 6, 12, and 24 months after infusion | Percentage of participants alive at the specified post-infusion follow-up times. As an uncomparative three-participant study, individual survival status and descriptive estimates will be reported. |
| Secondary | Event-Free Survival | 6, 12, and 24 months after infusion | Time from infusion to the first protocol-defined event or death. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07907172
GET https://conductscience.org/api/trials/v1/NCT07907172/registered